In the last five years, GLP-1 receptor agonists (GLP-1 RAs) have gone from being niche diabetes drugs to headline-grabbing weight-loss therapies. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are not only reshaping how we treat type 2 diabetes, but also redefining the entire conversation around obesity and metabolic health. The impact is enormous:→ More […]
Non-alcoholic fatty liver disease (NAFLD) and obesity are two of the fastest-growing health problems worldwide. In the U.S. alone, more than 100 million adults are estimated to have fatty liver, with many progressing toward non-alcoholic steatohepatitis (NASH), a serious condition that can lead to cirrhosis and liver failure. At the same time, nearly 42% of American […]
The last decade has seen an explosion of new therapies for obesity and metabolic disease, with GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) dominating headlines and prescriptions. These medications have redefined what’s possible for medical weight management, delivering double-digit weight loss percentages that rival surgical outcomes. But the race is far from […]
When it comes to restoring hormone balance, supporting fertility, or aiding recovery after anabolic steroid use, two compounds are frequently compared: Gonadorelin and HCG (human chorionic gonadotropin). Both play essential roles in regulating the hypothalamic–pituitary–gonadal (HPG) axis, yet they operate at different points along the pathway. Gonadorelin is a synthetic version of GnRH (gonadotropin-releasing hormone), the […]
The MOTS-c peptide is a newly discovered mitochondrial-derived peptide (MDP) that has quickly become one of the most intriguing topics in both longevity science and sports performance. Encoded by mitochondrial DNA, MOTS-c acts as a cellular messenger that helps regulate energy metabolism, glucose utilization, and stress adaptation. As noted by Lee, Cell Metabolism, MOTS-c improves insulin […]